115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
基于支气管肺泡灌洗液的靶向新一代测序技术在肺结核诊断及耐药检测中的应用研究
Authors Zhao CY, Song C, Huang XW , Huang AC, Zeng CM, Li WW, Tan QQ, Lin XS, Huang ZT, Jiang CY, Zhu QD
Received 29 September 2025
Accepted for publication 5 January 2026
Published 9 January 2026 Volume 2026:19 567798
DOI https://doi.org/10.2147/IDR.S567798
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Hemant Joshi
uangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China; 3Department of Pharmacy, The Fourth People’s Hospital of Nanning, Nanning, Guangxi, 530023, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Qing-Dong Zhu, Department of Tuberculosis, The Fourth People’s Hospital of Nanning, Nanning, Guangxi, 530023, People’s Republic of China, Email zhuqingdong2003@163.com Chang-Yue Jiang, Department of Pharmacy, The Fourth People’s Hospital of Nanning, Nanning, Guangxi, 530023, People’s Republic of China, Email 651642097@qq.com
Purpose: To evaluate the clinical value of targeted next-generation sequencing (tNGS) using bronchoalveolar lavage fluid (BALF) in diagnosing pulmonary tuberculosis (PTB) and detecting resistance to first-line anti-tuberculosis drugs, and to compare its performance with traditional methods.
Patients and Methods: In this study, BALF samples were collected from 258 patients with suspected PTB and subjected to AFB staining, mycobacterial solid culture, TB-DNA PCR, Xpert MTB/RIF, and tNGS. Using comprehensive clinical diagnosis or phenotypic DST as the reference, we evaluated the sensitivity, specificity, and other metrics of each method and assessed tNGS performance in detecting resistance to rifampicin, isoniazid, streptomycin, and ethambutol.
Results: Overall, tNGS achieved a sensitivity of 91.10%, specificity of 89.70%, and an AUC of 0.904, all significantly higher than traditional methods. It uniquely identified 24 positive cases missed by other methods. In smear-negative patients, sensitivity remained high at 88.10%, with an AUC of 0.891. For drug-resistance detection, tNGS showed the best performance in judging isoniazid resistance (sensitivity 83.10%, specificity 90.30%), and also showed high negative predictive values for rifampicin, streptomycin, and ethambutol (all > 94%).
Conclusion: tNGS provides excellent diagnostic accuracy for PTB and reliable detection of drug-resistant mutations from BALF samples. It is particularly suitable for smear-negative cases and for resistance screening, making it a powerful complement to the existing TB diagnosis system with high clinical application potential.
Keywords: targeted next-generation sequencing, bronchoalveolar lavage, tuberculosis, drug resistance, diagnostic efficacy
*These authors contributed equally to this work
Correspondence: Qing-Dong Zhu, Department of Tuberculosis, The Fourth People’s Hospital of Nanning, Nanning, Guangxi, 530023, People’s Republic of China, Email zhuqingdong2003@163.com Chang-Yue Jiang, Department of Pharmacy, The Fourth People’s Hospital of Nanning, Nanning, Guangxi, 530023, People’s Republic of China, Email 651642097@qq.com
Purpose: To evaluate the clinical value of targeted next-generation sequencing (tNGS) using bronchoalveolar lavage fluid (BALF) in diagnosing pulmonary tuberculosis (PTB) and detecting resistance to first-line anti-tuberculosis drugs, and to compare its performance with traditional methods.
Patients and Methods: In this study, BALF samples were collected from 258 patients with suspected PTB and subjected to AFB staining, mycobacterial solid culture, TB-DNA PCR, Xpert MTB/RIF, and tNGS. Using comprehensive clinical diagnosis or phenotypic DST as the reference, we evaluated the sensitivity, specificity, and other metrics of each method and assessed tNGS performance in detecting resistance to rifampicin, isoniazid, streptomycin, and ethambutol.
Results: Overall, tNGS achieved a sensitivity of 91.10%, specificity of 89.70%, and an AUC of 0.904, all significantly higher than traditional methods. It uniquely identified 24 positive cases missed by other methods. In smear-negative patients, sensitivity remained high at 88.10%, with an AUC of 0.891. For drug-resistance detection, tNGS showed the best performance in judging isoniazid resistance (sensitivity 83.10%, specificity 90.30%), and also showed high negative predictive values for rifampicin, streptomycin, and ethambutol (all > 94%).
Conclusion: tNGS provides excellent diagnostic accuracy for PTB and reliable detection of drug-resistant mutations from BALF samples. It is particularly suitable for smear-negative cases and for resistance screening, making it a powerful complement to the existing TB diagnosis system with high clinical application potential.
Keywords: targeted next-generation sequencing, bronchoalveolar lavage, tuberculosis, drug resistance, diagnostic efficacy